News

Stories

See all

Updates: Lilly's Global COVID-19 Response

View Story

Naming a New Drug During a Pandemic

View Story

Time to Tear Down the Rebate Wall

View Story

Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

View Story

When the World Called for Help with COVID-19, We Were Ready

View Story

Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

View Story


Press Releases

See all

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting

December 5, 2020

Tags |  Product

52% overall response rate in mantle cell lymphoma patients previously treated with a covalent BTK inhibitor 83% of responding mantle cell lymphoma patients remain in response and on therapy 68% overall response rate in patients with Waldenström's macroglobulinemia, 69% of whom were previously




Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19

December 4, 2020

Tags |  Product

The study brings together symptom tracking, in-home testing and in-home infusions to detect, intercept and treat COVID-19 early INDIANAPOLIS and MINNETONKA, Minn. , Dec. 4, 2020 /PRNewswire/ --   Eli Lilly and Company (NYSE: LLY) and UnitedHealth Group (NYSE: UNH) today announced a partnership to




Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19

December 2, 2020

Tags |  Product

INDIANAPOLIS , Dec. 2, 2020 /PRNewswire/ -- The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for $812.5 million and the doses will be delivered through January 31, 2021




Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

November 24, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a